Screener
Maravai LifeSciences Holdings, Inc. MRVI Impairment Charges
Impairment Charges at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001823239-26-000024
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Amortization of intangible assets | 6,472 | 7,030 |
| Amortization of operating lease right-of-use assets | 1,606 | 2,187 |
| Stock-based compensation expense | 6,743 | 10,403 |
| Impairment | 605 | 12,435 |
| Other | 541 | 225 |
| Changes in operating assets and liabilities, net of acquisitions: | ||
| Accounts receivable | (7,914) | 10,160 |
| Inventory | 33 | 449 |
Item 1. Financial Statements
FAQ
- What is Maravai LifeSciences Holdings, Inc.'s impairment charges?
- Maravai LifeSciences Holdings, Inc. (MRVI) reported impairment charges of $605K in Q1 2026.
- How has Maravai LifeSciences Holdings, Inc.'s impairment charges changed year-over-year?
- Maravai LifeSciences Holdings, Inc.'s impairment charges decreased by 95.1% year-over-year, from $12.44M to $605K.
- What does impairment charges mean?
- Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.
Ask your AI about Maravai LifeSciences Holdings, Inc.'s impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude